The anti-HLA-G scFv component may compete with LILRB1 and KIR2D4, both of which are expressed by NK cells, to hijack tumor HLA-G and activate NK cell cytotoxicity by downregulating phosphor-SHP-1 and upregulating phosphor-Syk/Zap70 (thereby converting inhibitory signals to activating signals) (figure 3E). Here, SYK is linked to neoplasm.